CN1562344A - Application of laevorotation carnosine in preparaing medication for assistant curing hepatitis and health foods - Google Patents
Application of laevorotation carnosine in preparaing medication for assistant curing hepatitis and health foods Download PDFInfo
- Publication number
- CN1562344A CN1562344A CNA2004100337789A CN200410033778A CN1562344A CN 1562344 A CN1562344 A CN 1562344A CN A2004100337789 A CNA2004100337789 A CN A2004100337789A CN 200410033778 A CN200410033778 A CN 200410033778A CN 1562344 A CN1562344 A CN 1562344A
- Authority
- CN
- China
- Prior art keywords
- carnosine
- handed
- hepatitis
- application
- laevorotation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
An application of levo-carnosine in preparing the medicine or health-care food for treating CCl4-toxipathic hepatitis and cocaine-toxipathic hepatitis is disclosed.
Description
Technical field
The present invention relates to the purposes of a kind of chemical compound in medicine and health food, specifically, is that left-handed carnosine is in the adjuvant therapy medicaments of preparation hepatitis and the purposes in the health food.
Background technology
In the middle of gastral disease, hepatopathy and gastric cancer are the disease kinds of serious harm people ' s health.China has 1.2 hundred million hepatitis B virus lifelong carriers at present approximately, and wherein 3,000 ten thousand people can be transformed into chronic hepatitis, liver cirrhosis, hepatocarcinoma, and annual people because of hepatopathy death has 300,000 people approximately.In recent years, along with improving constantly of living standards of the people, the fatty liver by being addicted to drink and causing with some other factor also increases day by day.China is used for the treatment of the expense of hepatopathy every year up to 40,000,000,000 yuans, and national economy and social development has been caused very big influence.Owing to still lack the method for specific treatment hepatitis at present, the new drug of exploitation treatment hepatopathy is very urgent and important.
Left-handed carnosine (L-carnosine) belongs to natural dipeptides, all exists in a lot of animal tissues.The physiological function of left-handed carnosine is also understood fully, it is believed that have promote that the injured tissues healing is restored, the damage of antagonism free radical and prolong function such as cell ageing.Left-handed carnosine synthetic has had the history of decades, is mainly used in the research in the laboratory at present.Still unmanned its medical value and the health food found is worth.
Summary of the invention
The new purposes that the purpose of this invention is to provide left-handed carnosine, i.e. new application in preparation hepatitis adjuvant therapy medicaments and health food.
Another object of the present invention provides a kind of medicine of hepatitis auxiliary treatment.
A further object of the present invention provides a kind of health food of hepatitis auxiliary treatment.
The inventor was according to " new drug preclinical study guideline " (1993, Bureau of Drugs Supervision of country) and " health food function assessment assessment process " (Ministry of Public Health, 2003) etc. the medicine and the health food method of hepatitis auxiliary treatment, left-handed carnosine has been carried out animal pharmacology and pathological study.
The inventor finds, carries out lumbar injection and oral administration with left-handed carnosine, and obvious effects is all arranged, and serum liver biochemical function index and pathological index all improve significantly.
When treating with left-handed carnosine, it can be with form oral administrations such as powder, granule, tablet, capsule, pill and liquid preparations; Also can be non-through enteral administration with forms such as injection, suppository, percutaneous preparation, inhalant.The effective agent of left-handed carnosine, be by with suitable medicinal blend, as mixing such as excipient, binding agent, penetrating agent, lubricants and be mixed with.
Dosage changes with patient's the state of an illness, route of administration, patient's age and body weight.Under the oral administration situation, dosage is generally adult 100～1000mg/ days, is preferably 100～200mg/ days.In the health food application facet also is same principle.
Aspect the safety of medicine and health food, the acute oral LD of the left-handed carnosine of report to mice arranged
50＞14.930g/kg.So left-handed carnosine belongs in fact nontoxic material basically, prompting is a kind of relatively material of safety.
Advantage of the present invention is: left-handed carnosine can be used as the chemical compound of cocaine poisoning hepatitis auxiliary treatment.Cocaine is popular analeptic drugs in a kind of world wide.2002 the end of the year China major drug-related cases of 100 kilograms of cocaine smugglings have just taken place.Hepatitis is the lethal major reason of cocaine poisoning.Also do not treat at present the generally acknowledged medicine of cocaine poisoning hepatitis in the world.Acting on internal and international of the antitoxin product cocaine of left-handed carnosine all is to find first.Except the hepar damnification of anti-cocaine, we also observe left-handed carnosine simultaneously has certain inhibitory action to the mice exaltation effect that cocaine brings out.
Left-handed carnosine is a kind of natural dipeptides that is present in the tissue such as animal muscle, externally suppresses the lipid oxidation effect that ferrum, hemoglobin, xanthine oxidase and singlet oxygen bring out, and can be used as a kind of oxidized form that the stores cold cuts inhibitor that becomes sour.Though also there is not the standard of left-handed carnosine normal contents value in vivo at present; also lack the excessive poisoning of left-handed carnosine or lack insufficient criterion; but our result of study demonstrates the protective effect of left-handed carnosine to body, and the prompting body is the serviceability of the suitable left-handed carnosine of supplemented with exogenous in some cases.
In addition, left-handed carnosine preparation method is fairly simple, relatively simple for structure, and physicochemical property is studied relatively more thoroughly.
The english name of left-handed carnosine is L-Carnosine (a L-carnosine).
Molecular formula: C
9H
14N
4O
3
Molecular weight: 226.23
CAS registration number: 305-84-0
Other name: N-β-Alanyl-L-histidine (N-β-alanyl-L-histidine).
Chemical constitution is:
The specific embodiment
The embodiment that provides below is used for further illustrating the present invention, and does not constitute limitation of the scope of the invention.
1. material
The used left-handed carnosine of embodiment provides product batch number BQ0205, content 99% by north, chemical reagent Beijing debridement industry scientific and technological development company limited.
Other medicine, reagent and laboratory animal can both be commercial easily.
2. preparation method example
Get left-handed carnosine 100g, hydroxyethyl-cellulose 10g, tabletting is made tablet, is placed in the vessel of normal temperature drying standby.
Left-handed carnosine is water-soluble, can directly use normal saline preparation injection on demand.
3. test method
The auxiliary treatment drug effect study portion of the anti-various drug intoxication hepatitis of left-handed carnosine
Laboratory animal is a male ICR mouse, and body weight is 22～26g, is provided by Department Of Medicine, Peking University's Experimental Animal Center.Duration of test provides the tap water and the normal diet of capacity, and animal housing keeps 22 ℃, automatic ventilation.The grouping of animal is pressed the body weight random packet with processing with mice.Toxic hepatitis modeling group did not give any processing in preceding 3 days, the 4th day subcutaneous injection modeling chemical compound.Left-handed carnosine+modeling compound component was not irritated stomach 4 days, every day 1 time No. six with various dose Chinese medicine.Behind the 4th day gastric infusion 30 minutes, subcutaneous or lumbar injection modeling compound solution.The contamination of modeling chemical compound is after 24 hours, and all animal endocanthions are got blood, and disconnected marrow is put to death; leave and take liver at once, weigh, maximum leaf is dipped in 10% the formalin fixing; carry out the observation of liver cardinal principle and leave and take liver specimens, the hepatic pathology intensity of variation is observed in HE dyeing.Utilize the 7170A automatic analyzer, adopt enzyme connection-ultraviolet continuous detecting method, measure alanine transaminase (ALT) and aspartate transaminase (AST) activity in the serum.The statistical analysis technique experimental data is represented with mean ± standard deviation.Use the SPSSl1.5 statistical software and experimental result is adopted methods analysts such as variance analysis, t check handle, p＜0.05 thinks that group difference has significance, and p＜0.01 thinks that group difference has highly significant.
4. result of the test:
(1) effect of the anti-carbon tetrachloride mice of left-handed carnosine toxic hepatitis can be referring to table 1.
(2) effect of left-handed carnosine anti-cocaine mice toxic hepatitis can be referring to table 2.
The effect (serological index) of the anti-carbon tetrachloride poisoning hepatitis of the left-handed carnosine of table 1 (x ± S)
Left-handed carnosine ALT AST
mg/kg (IU/L) (IU/L)
Matched group 32.8 ± 5.5 117.6 ± 12.5
Carbon tetrachloride model group 2279.2 ± 1090.0
##787.5 ± 400.5
##
800 1616.8±1115.3 824.4±464.9
1600 1207.0±1087.9 665.2±508.9
3200 230.8±180.0
** 197.6±98.6
**
Annotate:
##Compare p＜0.01 with matched group.
*Compare p＜0.01 with model group
The effect (serological index) of the left-handed carnosine anti-cocaine of table 2 toxic hepatitis (x ± S)
Left-handed carnosine dosage ALT AST
mg/kg (IU/L) (IU/L)
Matched group 30 ± 5 94 ± 6
Cocaine model group 3276 ± 1720
##733 ± 301
##
400 2655±1578 648±206
800 1730±1057 671±348
3200 549±422
** 292±144
*
##Compare p＜0.01 with matched group.
*Compare p＜0.05 with model group,
*Compare p＜0.01 with model group
Claims (4)
1. a medicine that is used for the hepatitis auxiliary treatment is characterized in that containing left-handed carnosine.
2. a health food that is used for the hepatitis auxiliary treatment is characterized in that containing left-handed carnosine.
3. left-handed carnosine is in the adjuvant therapy medicaments of preparation cocaine poisoning hepatitis and the application in the health food.
4. left-handed carnosine is in the adjuvant therapy medicaments of preparation carbon tetrachloride poisoning hepatitis and the application in the health food.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100337789A CN1263506C (en) | 2004-04-16 | 2004-04-16 | Application of laevorotation carnosine in preparaing medication for assistant curing hepatitis and health foods |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100337789A CN1263506C (en) | 2004-04-16 | 2004-04-16 | Application of laevorotation carnosine in preparaing medication for assistant curing hepatitis and health foods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1562344A true CN1562344A (en) | 2005-01-12 |
| CN1263506C CN1263506C (en) | 2006-07-12 |
Family
ID=34481393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100337789A Expired - Fee Related CN1263506C (en) | 2004-04-16 | 2004-04-16 | Application of laevorotation carnosine in preparaing medication for assistant curing hepatitis and health foods |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1263506C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108310362A (en) * | 2018-02-05 | 2018-07-24 | 中国人民解放军第四五八医院 | Application of the carnosine in terms of hepatitis virus resisting |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010226256B2 (en) * | 2009-03-20 | 2016-08-11 | Chef'n Corporation | Pouring device with deformable spout |
-
2004
- 2004-04-16 CN CNB2004100337789A patent/CN1263506C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108310362A (en) * | 2018-02-05 | 2018-07-24 | 中国人民解放军第四五八医院 | Application of the carnosine in terms of hepatitis virus resisting |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1263506C (en) | 2006-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1668293A (en) | Methods of using artemisinin-like compounds to prevent or delay the appearance of cancer | |
| CN111568945A (en) | Compound cyclocarya paliurus preparation | |
| CN1263506C (en) | Application of laevorotation carnosine in preparaing medication for assistant curing hepatitis and health foods | |
| CN110664850A (en) | Application of chaenomeles speciosa phenolic acid in protection of acute and chronic hypoxia injury | |
| CN1232249C (en) | Application of chalcone for preparing medicnes for treating hepatitis and hepatoma | |
| CN1201737C (en) | Application of cepharanthine in preparing medicine for resisting SARS virus | |
| CN1840172A (en) | Pidotimod solution capable of being administered from vein | |
| CN112138148B (en) | Oral pharmaceutical composition of growth hormone or analogue thereof | |
| CN1850072A (en) | Pharmaceutical use of alpha-(2,4-dichlorobenzyle)-1H-imidazole-1-ethanol for treating hepatitis | |
| CN1269487C (en) | Arsenic trioxide oral liquid and its preparation process | |
| CN100364540C (en) | Pharmaceutical use of (2s-cis)-(+)-2,3-dihydro-3-hydroxy-2-(4-methoxyphenyl)-1,5-benzothiazepine-4(5H)-one for treating hepatitis | |
| CN1284553C (en) | Application of five-finger fig in preparing adjuvant for treating hepatitis and health foods | |
| CN1130213C (en) | Chinese herbal plaster for anti-cancer and analgesic | |
| CN1120002C (en) | Application of ammonium nilrate in pharmaceutical industry, food and health-care product | |
| CN1272008C (en) | Application of diltiazem of hydrochloric acid in preparing antidote | |
| CN1188117C (en) | Application of 1, 3-diphenyl-1, 3-propanedione in preparing medicine for treating hepatitis | |
| Parsi et al. | Comparison of Garlic therapeutic effects and standard therapy with De Penicillamine in patients with Lead poisoning | |
| CN1778309A (en) | Use of arctiin and its aglycon in preparation of medicines for diabetes and nephrosis | |
| CN112121056A (en) | Application of composition of small-molecule fucoidin and fucoxanthin in preparation of composition for improving non-alcoholic fatty liver disease | |
| Macadangdang Jr et al. | Hypoglycemic Effect of Moringa Oliefera Lam. Seed Oil Extract and Royal Jelly Composite Mixture in Alloxan-Induced Diabetes in Male Albino Wistar Rats. Asian | |
| CN113476438B (en) | Hypoglycemic composition containing dihydro morin and application thereof | |
| CN113181173B (en) | Medicinal composition and application thereof in preparing products for preventing and/or treating liver cancer | |
| CN1291721C (en) | Use of allose alcohol in preparing medicine for diabetes | |
| RU2673555C2 (en) | Method for application yagel detox dietary supplement as means for treatment of multiple drug resistance tuberculosis | |
| Baniasad et al. | Hepatotoxicity due to mushroom poisoning: A case report |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060712 Termination date: 20130416 |